These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

924 related articles for article (PubMed ID: 31383813)

  • 21. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
    Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
    Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
    Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
    World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
    Cohen R; Bennouna J; Meurisse A; Tournigand C; De La Fouchardière C; Tougeron D; Borg C; Mazard T; Chibaudel B; Garcia-Larnicol ML; Svrcek M; Vernerey D; Menu Y; André T
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
    Almquist DR; Ahn DH; Bekaii-Saab TS
    BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Microsatellite Instability Testing in Management of Colorectal Cancer.
    Sun BL
    Clin Colorectal Cancer; 2021 Mar; 20(1):e12-e20. PubMed ID: 32888812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

  • 27. The therapeutic impact of programmed death - 1 in the treatment of colorectal cancer.
    Sangani PS; Yazdani S; Khalili-Tanha G; Ghorbani E; Al-Hayawi IS; Fiuji H; Khazaei M; Hassanian SM; Kiani M; Ghayour-Mobarhan M; Ferns GA; Nazari E; Avan A
    Pathol Res Pract; 2024 Jul; 259():155345. PubMed ID: 38805760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on the use of immunotherapy in patients with colorectal cancer.
    Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
    Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
    [No Abstract]   [Full Text] [Related]  

  • 29. [Checkpoint inhibitors in colorectal carcinoma: are we entering a new era?].
    Pox C
    Inn Med (Heidelb); 2023 May; 64(5):500-505. PubMed ID: 37039887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
    Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
    Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
    J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
    Kreidieh M; Mukherji D; Temraz S; Shamseddine A
    Biomed Res Int; 2020; 2020():9037217. PubMed ID: 32090113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer.
    Kanani A; Veen T; Søreide K
    Br J Surg; 2021 Dec; 108(12):1417-1425. PubMed ID: 34694371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the efficacy and safety of first- and second-line immunotherapy in patients with metastatic colorectal cancer: a systematic review and network meta-analysis based on randomized controlled trials.
    Chen K; Chen W; Yue R; Zhu D; Cui S; Zhang X; Jin Z; Xiao T
    Front Immunol; 2024; 15():1439624. PubMed ID: 39359729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy in colorectal cancer: current achievements and future perspective.
    Fan A; Wang B; Wang X; Nie Y; Fan D; Zhao X; Lu Y
    Int J Biol Sci; 2021; 17(14):3837-3849. PubMed ID: 34671202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.
    Franke AJ; Skelton WP; Starr JS; Parekh H; Lee JJ; Overman MJ; Allegra C; George TJ
    J Natl Cancer Inst; 2019 Nov; 111(11):1131-1141. PubMed ID: 31322663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer.
    Silva VS; Riechelmann RP; Mello CA; Felismino T; Taboada R
    Curr Cancer Drug Targets; 2022 Aug; 22(8):617-628. PubMed ID: 35209820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
    Zhu C; Han G; Wu B
    BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.